secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093991
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs
--------------------------------------------------------------------------------

- Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.
- Cash, equivalents & marketable securities $99.3M; sufficient into H2 2025; $45M SVB credit facility available, undrawn.
- TN-201 received FDA Rare Pediatric Disease Designation for MYBPC3-associated HCM; interim Phase 1b data expected H2 2024.
- TN-401 cleared by UK MHRA to start Phase 1b; 84% of screening volunteers eligible based on low AAV9 antibodies.
- CFO Leone Patterson departing Aug 14; CEO Faraz Ali interim PFO; Chihiro Saito interim PAO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/tnya-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer